CPL Launches Production of Hand-Sanitizer to Meet Critical Shortages

Mississauga, Ontario, Canada, April 9, 2020 — Contract Pharmaceuticals Limited Canada (CPL), a Health Canada and US FDA approved manufacturer of liquid and semi-solid prescription and OTC medicines, has begun production of its alcohol-based hand sanitizer to help meet the current market shortage during the ongoing COVID-19 pandemic.

With the urgent need for hand sanitizer in many commercial and industrial locations, CPL recently developed its product based on World Health Organization (WHO) and Centers for Disease Control (CDC) guidelines. The product is a hand sanitizer solution containing 80% alcohol and is available in both 60mL and 200mL bottles. CPL is currently manufacturing the product at its manufacturing and packaging operation in Mississauga, Ontario, Canada.

“CPL is one of the leading contract manufacturers of non-sterile liquid and topical prescription and OTC products in North America, and one of very few companies that have the proper equipment to safely produce alcohol-containing products,” said Jan Sahai, Vice President, Business Development at CPL. “As we saw the market shortage for these products unfold, we developed a formula for hand sanitizer solution, registered the product with Health Canada, and began manufacturing, packaging and testing the product within the past few weeks.”

The company is currently shipping the product across Canada to long-term care facilities, grocery store distribution centres, universities, and a variety of essential industries. “Many of these organizations are desperate for hand sanitizer products as the demand is great during this crisis,” says Sahai. “We are simply trying to do our part in this fight.”

One challenge for this product for all producers is the tight supply chains for components such as alcohol and plastic bottles. CPL is working closely with its long-term suppliers to maintain a consistent supply of the components for the product.

About CPL
CPL is a leading provider of product development and manufacturing services for non-sterile liquid and semi-solid pharmaceutical products and serves the pharmaceutical industry in North America, Europe, and Asia. Our facilities are registered by both the US FDA and Health Canada and support the development and commercial production of non-sterile solutions, suspensions, nasal sprays, and topical dosage forms such as creams, lotions, gels, and ointments.

For more information, please contact:

Jan Sahai
VP, Business Development